I wasn't trying to use those two examples to exactly compare with DXB but to draw upon how much management matters in terms of trial design and trusting them to not run a lifestyle company.
I definitely agree with understanding Biotechs can be a literal headache ;).
I wasn't trying to use those two examples to exactly...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $258.6M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 49.0¢ | 46.5¢ | $1.335M | 2.813M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10407 | 46.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.0¢ | 90768 | 11 |
View Market Depth
| Last trade - 14.14pm 29/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |